Literature DB >> 11238682

Male breast cancer in Cowden syndrome patients with germline PTEN mutations.

J D Fackenthal1, D J Marsh, A L Richardson, S A Cummings, C Eng, B G Robinson, O I Olopade.   

Abstract

Cowden syndrome (CS) (OMIM 158350) is a multiple hamartoma syndrome associated with germline mutations in the PTEN tumour suppressor gene. While CS is characterised most commonly by non-cancerous lesions (mucocutaneous trichilemmomas, acral and palmoplantar keratoses, and papillomatous papules), it is also associated with an increased susceptibility to breast cancer (in females) and thyroid cancer, as well as non-cancerous conditions of the breast and thyroid. Here we report two cases of male breast cancer occurring in patients with classical CS phenotypes and germline PTEN mutations. The first subject was diagnosed with CS indicated primarily by mucocutaneous papillomatosis, facial trichilemmomas, and macrocephaly with frontal bossing at the age of 31 years. He developed breast cancer at 41 years and subsequently died of the disease. A PTEN mutation, c.802delG, was identified in this subject, yet none of his family members showed evidence of a CS phenotype, suggesting that this PTEN mutation may be a de novo occurrence. The second subject had a CS phenotype including multiple trichilemmomas and thyroid adenoma, developed male breast cancer at 43 years, and died of the disease at 57 years. He was a carrier of a PTEN mutation c.347-351delACAAT that cosegregated with the CS phenotype in affected family members. These two cases of male breast cancer associated with germline PTEN mutations and the CS phenotype suggest that CS may be associated with an increased risk of early onset male as well as female breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238682      PMCID: PMC1734834          DOI: 10.1136/jmg.38.3.159

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  53 in total

Review 1.  Carcinoma of the male breast and Klinefelter's syndrome: is there an association?

Authors:  D B Evans; R W Crichlow
Journal:  CA Cancer J Clin       Date:  1987 Jul-Aug       Impact factor: 508.702

2.  Cowden's disease (multiple hamartoma syndrome).

Authors:  H D Gilbert; R A Plezia; T Pietruk
Journal:  J Oral Maxillofac Surg       Date:  1985-06       Impact factor: 1.895

Review 3.  Cowden's disease.

Authors:  D S Bardenstein; I W McLean; J Nerney; R S Boatwright
Journal:  Ophthalmology       Date:  1988-08       Impact factor: 12.079

4.  Lack of c-erbB-2 oncoprotein expression in male breast carcinoma.

Authors:  S B Fox; C A Day; S Rogers
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

5.  Breast cancer in men: risk factors with hormonal implications.

Authors:  D B Thomas; L M Jimenez; A McTiernan; K Rosenblatt; H Stalsberg; A Stemhagen; W D Thompson; M G Curnen; W Satariano; D F Austin
Journal:  Am J Epidemiol       Date:  1992-04-01       Impact factor: 4.897

6.  Bannayan-Riley-Ruvalcaba syndrome.

Authors:  R J Gorlin; M M Cohen; L M Condon; B A Burke
Journal:  Am J Med Genet       Date:  1992-10-01

7.  A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10.

Authors:  C G Mathew; K S Chin; D F Easton; K Thorpe; C Carter; G I Liou; S L Fong; C D Bridges; H Haak; A C Kruseman
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

8.  Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature.

Authors:  O S Salem; W D Steck
Journal:  J Am Acad Dermatol       Date:  1983-05       Impact factor: 11.527

9.  The Cowden syndrome: a clinical and genetic study in 21 patients.

Authors:  T M Starink; J P van der Veen; F Arwert; L P de Waal; G G de Lange; J J Gille; A W Eriksson
Journal:  Clin Genet       Date:  1986-03       Impact factor: 4.438

10.  Cowden's disease (multiple hamartoma syndrome).

Authors:  H N Thyresson; J A Doyle
Journal:  Mayo Clin Proc       Date:  1981-03       Impact factor: 7.616

View more
  36 in total

1.  Cowden syndrome: mucocutaneous lesions as precursors of internal malignancy.

Authors:  Panagiotis Stathopoulos; Anna Raymond; Michael Esson
Journal:  Oral Maxillofac Surg       Date:  2014-04-01

Review 2.  An updated review of epidemiology, risk factors, and management of male breast cancer.

Authors:  Noman Ahmed Jang Khan; Maria Tirona
Journal:  Med Oncol       Date:  2021-03-15       Impact factor: 3.064

Review 3.  Hamartomatous polyposis syndromes.

Authors:  Daniel Calva; James R Howe
Journal:  Surg Clin North Am       Date:  2008-08       Impact factor: 2.741

4.  Male Breast Cancer: A Study in Small Steps.

Authors:  Larissa A Korde
Journal:  Oncologist       Date:  2015-05-18

5.  [Multiple hemangiomas, polyposis coli, endometrial and papillary thyroid cancer].

Authors:  J Kionke; T Grundmann; C Bullmann; B Auber
Journal:  Internist (Berl)       Date:  2012-05       Impact factor: 0.743

Review 6.  Risk assessment and management of high risk familial breast cancer.

Authors:  D G R Evans; F Lalloo
Journal:  J Med Genet       Date:  2002-12       Impact factor: 6.318

Review 7.  PTEN hamartoma tumor syndromes.

Authors:  Gideon M Blumenthal; Phillip A Dennis
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

8.  Male breast cancer presenting with bilateral pleural effusion.

Authors:  Saurabh Karmakar; Tamojit Chaudhuri; Alok Nath; Zafar Neyaz
Journal:  N Am J Med Sci       Date:  2013-01

9.  Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases.

Authors:  Y M C Hendriks; J T C M Verhallen; J J van der Smagt; S G Kant; Y Hilhorst; L Hoefsloot; K B-M Hansson; P J C van der Straaten; H Boutkan; M H Breuning; H F A Vasen; A H J T Bröcker-Vriends
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 10.  Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Dawn C Allain
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.